Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of ILS 35.00 million. The enterprise value is 22.86 million.
Market Cap | 35.00M |
Enterprise Value | 22.86M |
Important Dates
The last earnings date was Sunday, November 17, 2024.
Earnings Date | Nov 17, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Evogene has 5.37 million shares outstanding. The number of shares has increased by 21.04% in one year.
Current Share Class | n/a |
Shares Outstanding | 5.37M |
Shares Change (YoY) | +21.04% |
Shares Change (QoQ) | +0.57% |
Owned by Insiders (%) | 1.57% |
Owned by Institutions (%) | 5.16% |
Float | 4.97M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.92 |
PB Ratio | 2.88 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.31 |
EV / Sales | 0.64 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.30 |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.04.
Current Ratio | 1.58 |
Quick Ratio | 1.32 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | -0.04 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -82.37% and return on invested capital (ROIC) is -50.33%.
Return on Equity (ROE) | -82.37% |
Return on Assets (ROA) | -28.46% |
Return on Capital (ROIC) | -50.33% |
Revenue Per Employee | 250,538 |
Profits Per Employee | -526,769 |
Employee Count | 142 |
Asset Turnover | 0.20 |
Inventory Turnover | 3.37 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.78% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -73.78% |
50-Day Moving Average | 911.52 |
200-Day Moving Average | 1,923.24 |
Relative Strength Index (RSI) | 25.37 |
Average Volume (20 Days) | 111,925 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Evogene had revenue of ILS 35.58 million and -74.80 million in losses. Loss per share was -14.89.
Revenue | 35.58M |
Gross Profit | 28.96M |
Operating Income | -80.86M |
Pretax Income | -79.19M |
Net Income | -74.80M |
EBITDA | -74.07M |
EBIT | -80.86M |
Loss Per Share | -14.89 |
Balance Sheet
The company has 78.72 million in cash and 3.05 million in debt, giving a net cash position of 75.67 million or 14.10 per share.
Cash & Cash Equivalents | 78.72M |
Total Debt | 3.05M |
Net Cash | 75.67M |
Net Cash Per Share | 14.10 |
Equity (Book Value) | 75.08M |
Book Value Per Share | 2.27 |
Working Capital | 35.73M |
Cash Flow
In the last 12 months, operating cash flow was -74.58 million and capital expenditures -1.78 million, giving a free cash flow of -76.36 million.
Operating Cash Flow | -74.58M |
Capital Expenditures | -1.78M |
Free Cash Flow | -76.36M |
FCF Per Share | -14.23 |
Margins
Gross margin is 81.42%, with operating and profit margins of -227.27% and -210.26%.
Gross Margin | 81.42% |
Operating Margin | -227.27% |
Pretax Margin | -222.59% |
Profit Margin | -210.26% |
EBITDA Margin | -208.19% |
EBIT Margin | -227.27% |
FCF Margin | -214.64% |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -21.04% |
Shareholder Yield | -21.04% |
Earnings Yield | n/a |
FCF Yield | n/a |
Stock Splits
The last stock split was on July 28, 2024. It was a reverse split with a ratio of 0.1.
Last Split Date | Jul 28, 2024 |
Split Type | Reverse |
Split Ratio | 0.1 |
Scores
Evogene has an Altman Z-Score of -9.26. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -9.26 |
Piotroski F-Score | n/a |